

Effective Date: January 1, 2022

Program: Ambulatory

### **Chapter: Medication Management**

#### Overview:

Medication management is an important component in the palliative, symptomatic, and curative treatment of many diseases and conditions. However, medications are also capable of causing great harm if the incorrect dose or medication is inadvertently administered to a patient. To eliminate any potential harm that could be caused by medications, organizations need to develop an effective and safe medication management system.

A safe medication management system addresses an organization's medication processes, which in many organizations include the following (as applicable):

- Planning
- Selection and procurement
- Storage
- Ordering
- Preparing and dispensing
- Administration
- Monitorina
- Evaluation

The "Medication Management" (MM) chapter addresses these critical processes, including those undertaken by the organization and those provided through contracted pharmacy services. However, the specifics of the medication management system used by the organization can vary depending on the care, treatment, or services it provides. Not all organizations will implement all of the medication processes. For example, organizations without pharmacy services will conduct the medication ordering process and will provide patients with prescriptions.

Effective and safe medication management also involves multiple services and disciplines working closely together. The medication management standards address activities involving various individuals, such as licensed independent practitioners and staff, within an organization's medication management system.

In addition, an effective medication management system includes mechanisms for reporting potential and actual medication-related errors and a process to improve medication management processes and patient safety based on this information.

In essence, a well-planned and implemented medication management system supports patient safety and improves the quality of care by doing the following:

- Reducing variation, errors, and misuse
- Using evidence-based practices to develop medication management processes
- Managing critical processes to promote safe medication management throughout the organization
- Standardizing equipment and handling processes, including those for sample medications, across the organization to improve the medication management system
- Monitoring the medication management process for efficiency, quality, and safety

## About This Chapter:

The goal of the medication management standards is to provide a framework for an effective and safe medication management system. Effective and safe medication management is dependent on carefully implementing medication management processes based on the care, treatment, or services provided by the organization. Planning provides the groundwork for the following critical areas of performance outlined in this chapter:

- Managing high-alert and hazardous medications
- Selecting and procuring medications
- Storing medications
- Managing emergency medications
- Controlling medications brought into the organization by patients, their families, and licensed independent practitioners
- Managing medication orders
- Preparing medications
- Labeling medications
- Dispensing medications
- Retrieving recalled or discontinued medications
- Administering medications
- Managing investigational medications
- Monitoring patients' reactions to medications
- Responding to real or potential adverse drug events, adverse drug reactions, and medication errors

Selected elements of performance (EPs) that are applicable to sample medications include a note that states, "This element of performance is also applicable to sample medications." The Joint Commission is not endorsing the use of sample medications. The note is only intended to identify which Medication Management EPs are applicable to sample medications for organizations that permit their use. Medication Management EPs that do not include this note are not applicable to sample medications.

# **Chapter Outline:**

- I. Planning
  - A. Medication Planning (MM.01.01.01, MM.01.01.03)
  - B. Look-alike/Sound-alike Medications (MM.01.02.01)
- II. Selection and Procurement (MM.02.01.01)

- III. Storage (MM.03.01.01, MM.03.01.03, MM.03.01.05)
- IV. Ordering and Transcribing (MM.04.01.01)
- $V.\ Preparing\ and\ Dispensing\ (MM.05.01.01,\ MM.05.01.07,\ MM.05.01.09,\ MM.05.01.11,\ MM.05.01.15,\ MM.05.01.17,\ MM.05.01.19)$
- VI. Administration (MM.06.01.01, MM.06.01.05)
- VII. Monitoring (MM.07.01.01, MM.07.01.03)
- VIII. Evaluation (MM.08.01.01)
- IX. Antimicrobial Stewardship (MM.09.01.03)

# **EP Attributes Icon Legend:**

CMS Crosswalk

**D** Documentation is required

**ESP-1** EP applies to Early Survey Option

**NEW** EP is new or changed as of the selected effective date.

Program: Ambulatory	

## MM.01.01.01: The organization plans its medication management processes.

**Rationale:** Medication management is often complicated, involving many people and processes. For this reason, the organization plans each part of the process with care so that safety and quality are maintained. This planning may involve the coordinated efforts of multiple services and disciplines.

Introduction: Not applicable

### **Elements of Performance**

- 1 The organization follows a written policy that describes that the following information about the patient is accessible to licensed independent practitioners and staff who participate in the management of the patient's medications:
  - Age
  - Sex
  - Diagnoses
  - Allergies
  - Sensitivities
  - Current medications
  - Height and weight (when necessary)
  - Pregnancy and lactation information (when necessary)
  - Laboratory results (when necessary)
  - Any additional information required by the organization

Note 1: This element of performance does not apply in emergency situations.

Note 2: This element of performance is also applicable to sample medications. (See also IM.02.01.01, EP 3)

### **EP Attributes**

New	FSA	CMS	DOC	ESP
			D	ESP-1

### MM.01.01.03: The organization safely manages high-alert and hazardous medications.

**Rationale:** High-alert medications are those medications that bear a heightened risk of causing significant patient harm and/or sentinel events when they are used in error and, as a result, require special safeguards to reduce the risk of errors. Examples of high-alert medications include opioids, insulin, anticoagulants, and neuromuscular blocking agents. Lists of high-alert medications are available from organizations such as the Institute for Safe Medication Practices (ISMP).

Hazardous drugs and medications are those in which studies in animals or humans indicate that exposure to them has a potential for causing cancer, developmental or reproductive toxicity, genotoxicity, or harm to organs. An example of a hazardous drug is one that contains antineoplastic agents or other ingredients that cause the aforementioned risks. Lists of hazardous drugs are available from the National Institute for Occupational Safety and Health (NIOSH).

For safe management, the organization needs to develop its own lists of both high-alert medications and hazardous drugs. These should be based on the organization's unique utilization patterns, its own internal data about medication errors and sentinel events, and known safety issues published in professional literature. It is up to the organization to determine whether medications that are new to the market are high alert or hazardous. In addition, the organization may separately choose to include other drugs that require special precautions such as investigational medications, controlled substances, and psychotherapeutic medications.

Note: For a list of high-alert medications, see https://www.ismp.org/recommendations. For a list of hazardous drugs, see https://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf.

Introduction: Not applicable

### **Elements of Performance**

The organization identifies, in writing, its high-alert and hazardous medications. \*

Note: This element of performance is also applicable to sample medications.

Footnote \*: For a list of high-alert medications, see https://www.ismp.org/recommendations. For a list of hazardous drugs, see https://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf. (See also EC.02.02.01, EP 1)

#### **EP Attributes**

New	FSA	CMS	DOC	ESP
	- Medication Management	§414.68(c)(1)(iv)	D	ESP-1

The organization follows a process for managing high-alert and hazardous medications.

Note: This element of performance is also applicable to sample medications. (See also EC.02.02.01, EP 8; MM.03.01.01, EP 9)

# **EP Attributes**

New	FSA	CMS	DOC	ESP
	- Medication Management	8414 68(c)(1)(iv)		

	Program: Ambulatory	
Chapter: Medication Management		

 ${\bf MM.01.02.01:}\ The\ organization\ addresses\ the\ safe\ use\ of\ look-alike/sound-alike\ medications.$ 

Rationale: Not applicable.

Introduction: Not applicable

### **Elements of Performance**

The organization develops a list of look-alike/sound-alike medications it stores, dispenses, or administers.

Note 1: One source of look-alike/sound-alike medication name pairs is the Institute for Safe Medication Practices (https://www.ismp.org/recommendations/confused-drug-names-list).

Note 2: This element of performance is also applicable to sample medications.

### **EP Attributes**

New	FSA	CMS	DOC	ESP
	- Medication Man	agement	D	ESP-1

2 The organization takes action to prevent errors involving the interchange of the medications on its list of look-alike/sound-alike medications.

Note: This element of performance is also applicable to sample medications.

### **EP Attributes**

		New	FSA	CMS	DOC	ESP
--	--	-----	-----	-----	-----	-----

<sup>-</sup> Medication Management

The organization annually reviews and, as necessary, revises its list of look-alike/sound-alike medications. Note: This element of performance is also applicable to sample medications.

### **EP Attributes**

New	FSA	CMS	DOC	ESP

apte	er: Medication Mana	gement			
ММ	.02.01.01: The orga	nization selects and	procures medications.		
Rat	ionale: Not applicable	e.			
Int	roduction: Not appli	cable			
Ele	ments of Performan	ce			
1			ermining which medications are a applicable to sample medication		nistering to patients.
	EP Attributes				
	New	FSA	CMS	DOC	ESP
2			approved by the organization and applicable to sample medication		fectiveness, and risks.
	EP Attributes				
	New	FSA	CMS	DOC	ESP
1	readily available to Note: Sample med	FSA naintains a written list o those involved in medi ications are not require	CMS  f medications, including strength cation management. d to be on this list.	DOC and dosage, for dispensing an	ESP d administering. The list is
	EP Attributes	FSA	CMS	DOC	ESP
	New	r5A	CM2	D	ESP-1
5	The organization st	candardizes and limits t	he number of drug concentration	s available in the organization.	
	EP Attributes				
	New	FSA	CMS	DOC	ESP
7			ct and procure medications that a applicable to sample medication		s.
	New	FSA	CMS	DOC	ESP
9	Medications design efficacy information		spensing or administration are re	viewed at least annually based	on emerging safety and
	FP Attributes				

New	FSA	CMS	DOC	ESP
	illows a process to commedication managemen	municate medication shortages a it.	nd outages to licensed indepe	ndent practitioners ar
P Attributes				
New	FSA	CMS	DOC	ESP
he organization fo	llows written medicatio	n substitution protocols to be us	ed in the event of a medication	n shortage or outage.
	llows written medicatio	n substitution protocols to be us	ed in the event of a medicatior	n shortage or outage.
The organization fo  EP Attributes  New	illows written medicatio	n substitution protocols to be us CMS	ed in the event of a medication  DOC	shortage or outage.
EP Attributes				
EP Attributes  New  The organization fo	FSA		DOC  D  stion protocols for shortages or	ESP

		Progra	m: Ambulatory		
pte	: Medication Manage	ment			
IM.	03.01.01: The organiz	zation safely stores medication	s.		
ini	nize the risk of medicat	ge is designed to assist in maintain ion diversion, and reduce potential proach to medication storage.			
ntr	oduction: Not applicab	ole			
len	ents of Performance				
en	ents of Performance				
len	The organization store	es medications according to the ma performance is also applicable to s		ns.	
	The organization store	es medications according to the ma		ns.	
	The organization store Note: This element of	es medications according to the ma		ns. DOC	ESP

### **EP Attributes**

**Chapter: Medication Management** 

New	FSA	CMS	DOC	ESP
		§416.48		

The organization safely handles medications between receipt by licensed independent practitioners or staff and administration of the 4

Note: This element of performance is also applicable to sample medications.

# **EP Attributes**

New	FSA	CMS	DOC	ESP

The organization prevents unauthorized individuals from obtaining medications in accordance with its policy and law and regulation. 6 Note: This element of performance is also applicable to sample medications.

### **EP Attributes**

New	FSA	CMS	DOC	ESP
\ <u></u>		§416.48		

7 All stored medications and the components used in their preparation are labeled with the contents, expiration date, and any applicable warnings.

Note: This element of performance is also applicable to sample medications.

## **EP Attributes**

New	FSA	CMS	DOC	ESP
		§416.48 §414.68(c)(1)(iv)		

The organization removes all expired, damaged, and/or contaminated medications and stores them separately from medications available for administration.

Note: This element of performance is also applicable to sample medications.

# **EP Attributes**

New	FSA	CMS	DOC	ESP

The organization keeps concentrated electrolytes present in patient care areas only when patient safety necessitates their immediate use, and precautions are used to prevent inadvertent administration. (See also MM.01.01.03, EP 2)

# **EP Attributes**

New	FSA	CMS	DOC	ESP
	- Medication Management	§416.48		

18 The organization periodically inspects all medication storage areas.

Note: This element of performance is also applicable to sample medications.

## **EP Attributes**

 New	FSA	CMS	DOC	ESP
		§414.68(c)(1)(iv)		

			Program: Ambulatory		
Chapte	er: Medication Manage	ment			
мм	.03.01.03: The organiz	zation safely manage	s emergency medications.		
eme	ergencies and what medi	cations and supplies it v	health care settings. The organizat will need. Although the processes m s medications in nonemergency sett	nay be different, the organizati	
Int	roduction: Not applicat	ole			
Ele	ments of Performance				
1			nergency medications and their asso ever possible, emergency medicatio		
	EP Attributes				
	New	FSA	CMS	DOC	ESP
6	When emergency med stock.	dications or supplies are	used or expired, the organization	replaces them as soon as poss	ible to maintain a full
	EP Attributes				

@ 2022 The Joint Commission, @ 2022 Joint Commission Resources E-dition is a registered trademark of The Joint Commission

CMS

FSA

New

DOC

ESP

			Program: Ambulatory		
Chapte	er: Medication Manage	ment			
	.03.01.05: The organize		medications brought into the c	organization by patients, the	eir families, or licensed
con		lications in order to pro	wing the patient to use their own n tect the safety of the patient and t of these medications.		
Int	roduction: Not applicab	ole			
Ele	ments of Performance				
1	practitioners can be a	dministered.	rought into the organization by pat plicable to sample medications.	cients, their families, or license	d independent
	EP Attributes				
	New	FSA	CMS	DOC	ESP
2	practitioner, the organ	nization identifies the m	brought into the organization by a edication and visually evaluates the plicable to sample medications. (Se	e medication's integrity.	sed independent
	EP Attributes				

@ 2022 The Joint Commission, @ 2022 Joint Commission Resources E-dition is a registered trademark of The Joint Commission

CMS

DOC

ESP

New

FSA

Pro	ogram: Ambulatory		

MM.04.01.01: Medication orders are clear and accurate.

Rationale: Not applicable.

Introduction: Introduction to Standard MM.04.01.01

Medication errors may occur when staff are communicating or transcribing medication orders. Verbal and telephone orders are particularly susceptible to error. The organization is responsible for reducing the potential for medication errors and the misinterpretation of these medication orders. As part of this process, the organization determines the required elements of a medication order, the type of medication orders that are deemed acceptable for use, and the actions to take when medication orders are incomplete, illegible, or unclear. Clear understanding and communication between staff and licensed independent practitioners involved in the medication process are essential.

#### **Elements of Performance**

- The organization follows a written policy that identifies the specific types of medication orders that it deems acceptable for use. Note: There are several different types of medication orders. Medication orders commonly used include the following:
  - As needed (PRN) orders: Orders acted on based on the occurrence of a specific indication or symptom
  - Standing orders: A prewritten medication order and specific instructions from the licensed independent practitioner to administer a medication to a person in clearly defined circumstances
  - Automatic stop orders: Orders that include a date or time to discontinue a medication
  - Titrating orders: Orders in which the dose is either progressively increased or decreased in response to the patient's status
  - Taper orders: Orders in which the dose is decreased by a particular amount with each dosing interval
  - Range orders: Orders in which the dose or dosing interval varies over a prescribed range, depending on the situation or patient's status
  - Signed and held orders: New prewritten (held) medication orders and specific instructions from a licensed independent practitioner to administer medication(s) to a patient in clearly defined circumstances that become active upon the release of the orders on a specific date(s) and time(s)
  - Orders for compounded drugs or drug mixtures not commercially available
  - Orders for medication-related devices (for example, nebulizers, catheters)
  - Orders for investigational medications
  - Orders for herbal products
  - Orders for medications at the end of an episode of care, or at discharge or transfer

### **EP Attributes**

New	FSA	CMS	DOC	ESP
			D	

- 2 The organization follows a written policy that defines the following:
  - The minimum required elements of a complete medication order, which must include medication name, medication dose, medication route, and medication frequency
  - When indication for use is required on a medication order
  - The precautions for ordering medications with look-alike or sound-alike names
  - Actions to take when medication orders are incomplete, illegible, or unclear
  - For medication titration orders, required elements include the medication name, medication route, initial rate of infusion (dose/unit of time), incremental units to which the rate or dose can be increased or decreased, how often the rate or dose can be changed, the maximum rate or dose of infusion, and the objective clinical measure to be used to guide changes

Note: Examples of objective clinical measures to be used to guide titration changes include blood pressure, Richmond Agitation–Sedation Scale (RASS), and the Confusion Assessment Method (CAM).

## **EP Attributes**

New	FSA	CMS	DOC	ESP
			D	ESP-1

7 If the organization uses preprinted medication order sheets, it updates them based on current evidence and practice.

### **EP Attributes**

New	FSA	CMS	DOC	ESP

8 The organization prohibits summary (blanket) orders to resume previous medications.

### **EP Attributes**

				505
New	FSA	CMS	DOC	ESP

			Program: Ambulatory		
napte	er: Medication Manage	ment			
	.05.01.01: The organizanization.	zation reviews the ap	propriateness of all medication	orders for medications to	be dispensed in the
Rat	cionale: Not applicable.				
Int	roduction: Not applicab	ble			
Ele	ments of Performance				
1		nes who can review med with law and regulation	lication orders or prescriptions for ( ).	dispensed medications, and u	nder what conditions this
	EP Attributes				
	N	FSA	CMS	DOC	ESP
	New				
	New				
4	All medication orders - Patient allergies or p - Existing or potential - The appropriateness	interactions between the of the medication, dose impact as indicated by tion	ne medication ordered and food and e, frequency, and route of administ		urrently taking
4	All medication orders - Patient allergies or p - Existing or potential - The appropriateness - Current or potential - Therapeutic duplicat	octential sensitivities interactions between the of the medication, dose impact as indicated by ion	ne medication ordered and food and e, frequency, and route of administ		urrently taking
4	All medication orders - Patient allergies or p - Existing or potential - The appropriateness - Current or potential - Therapeutic duplicat - Other contraindication	octential sensitivities interactions between the of the medication, dose impact as indicated by ion	ne medication ordered and food and e, frequency, and route of administ		urrently taking ESP

 $\ dispensing.$ 

# **EP Attributes**

New	FSA	CMS	DOC	ESP

## **Chapter: Medication Management**

MM.05.01.07: The organization safely prepares medications.

Note: This standard is applicable to all organizations that prepare medications for administration.

Rationale: Not applicable.

Introduction: Not applicable

### **Elements of Performance**

1 When an on-site licensed pharmacy is available, a pharmacist, or pharmacy staff under the supervision of a pharmacist, compounds or admixes all compounded sterile preparations except in urgent situations in which a delay could harm the patient or when the product's stability is short.

### **EP Attributes**

New	FSA	CMS	DOC	ESP

2 Staff use clean or sterile techniques and maintain clean, uncluttered, and functionally separate areas for product preparation to avoid contamination of medications.

### **EP Attributes**

New	FSA	CMS	DOC	ESP
	- Medication Management	§416.48(a) §414.68(c)(1)(iv)		

During preparation, staff visually inspect the medication for particulates, discoloration, or other loss of integrity. 3

### **EP Attributes**

New	FSA	CMS	DOC	ESP
	- Medication Management	§416.48 §416.48(a) §414.68(c)(1)(iv)		

#### **Chapter: Medication Management**

MM.05.01.09: Medications are labeled.

Note: This standard is applicable to all organizations that prepare and administer medications.

**Rationale:** A label on every medication and medication container has long been a standard of practice by the pharmacy profession and is required by law and regulation. A standardized method to label medications and containers promotes medication safety.

Introduction: Not applicable

### **Elements of Performance**

1 Medication containers are labeled whenever medications are prepared but not immediately administered.

Note 1: An organization that exclusively uses a single medication in a patient care area can draw up or prepare multiple doses for later use as long as the medication is segregated and secured from all other medications in the organization (for example, a vaccine, flu shot) and the container holding the individual doses is labeled.

Note 2: An immediately administered medication is one that an authorized staff member prepares or obtains, takes directly to a patient, and administers to that patient without any break in the process.

Note 3: This element of performance is also applicable to sample medications.

#### **EP Attributes**

New	FSA	CMS	DOC	ESP
	- Medication Management	§416.48 §416.48(a) §414.68(c)(1)(iv)		

2 Information on medication labels is displayed in a standardized format, in accordance with law and regulation and standards of practice. Note: This element of performance is also applicable to sample medications.

#### **EP Attributes**

_	New	FSA	CMS	DOC	ESP
			8414 68(c)(1)(iv)		

- 3 All medications prepared in the organization are correctly labeled with the following:
  - Medication name, strength, and amount (if not apparent from the container)

Note: This is also applicable to sample medications.

- Expiration date when not used within 24 hours
- Expiration date and time when expiration occurs in less than 24 hours
- The date prepared and the diluent for all compounded intravenous admixtures and parenteral nutrition formulas

### **EP Attributes**

New	FSA	CMS	DOC	ESP
	- Medication Management	§416.48 §416.48(a) §414.68(c)(1)(iv)		

- 7 When preparing individualized medications for multiple patients, the label also includes the following:
  - The patient's name
  - The location where the medication is to be delivered
  - Directions for use and applicable accessory and cautionary instructions (See also NPSG.01.01.01, EP 1)

### **EP Attributes**

New	FSA	CMS	DOC	ESP
	- Medication Management	§416.48 §414.68(c)(1)(iv)		

- When an individualized medication(s) is prepared by someone other than the person administering the medication, the label includes the following:
  - The patient's name
  - The location where the medication is to be delivered
  - Directions for use and applicable accessory and cautionary instructions (See also NPSG.01.01.01, EP 1)

## **EP Attributes**

New FSA CMS DOC ESP

- Medication Management

§416.48 §414.68(c)(1)(iv)

## **Chapter: Medication Management**

MM.05.01.11: The organization safely dispenses medications.

Rationale: Not applicable.

Introduction: Not applicable

### **Elements of Performance**

2 The organization dispenses medications and maintains clinical records in accordance with law and regulation, licensure, and professional standards of practice.

Note 1: Dispensing practices and recordkeeping include antidiversion strategies. Note 2: This element of performance is also applicable to sample medications.

### **EP Attributes**

New	FSA	CMS	DOC	ESP

§416.48

Program: Ambulatory	

 ${\bf MM.05.01.15:}\ The\ organization\ safely\ obtains\ medications\ when\ it\ does\ not\ operate\ a\ pharmacy.$ 

Rationale: Not applicable.

Introduction: Not applicable

### **Elements of Performance**

1 If the organization does not operate a pharmacy, the organization follows a process for obtaining medications from a pharmacy or licensed pharmaceutical supplier to meet patient needs.

## **EP Attributes**

New	FSA	CMS	DOC	ESP
-				

ESP-1

Program: Ambulatory		

MM.05.01.17: The organization follows a process to retrieve recalled or discontinued medications.

Note: This standard is applicable to all organizations that dispense medications, including sample medications.

Rationale: Not applicable.

Introduction: Not applicable

### **Elements of Performance**

The organization follows a written policy describing how it will retrieve and handle medications within the organization that are recalled or discontinued for safety reasons by the manufacturer or the US Food and Drug Administration (FDA).

Note: This element of performance is also applicable to sample medications. (See also EC.02.01.01, EP 11)

### **EP Attributes**

New	FSA	CMS	DOC	ESP
		§414.68(c)(1)(iv)	D	ESP-1

When a medication is recalled or discontinued for safety reasons by the manufacturer or the US Food and Drug Administration (FDA), the organization notifies the prescribers and those who dispense or administer the medication.

Note: This element of performance is also applicable to sample medications. (See also EC.02.01.01, EP 11)

#### **EP Attributes**

New FSA CMS DOC	ESP

§414.68(c)(1)(iv)

When required by law and regulation or organization policy, the organization informs patients that their medication has been recalled or discontinued for safety reasons by the manufacturer or the US Food and Drug Administration (FDA).
Note: This element of performance is also applicable to sample medications. (See also EC.02.01.01, EP 11)

### **EP Attributes**

New FSA CMS DOC ESP
---------------------

§414.68(c)(1)(iv)

Chapte	er: Medication Manage	ement			
мм	.05.01.19: The organi	zation safely manage	es returned medications.		
but			ganization when allowed by law or e organization must be accounted		
Intr	oduction: Not applica	ble			
Eler	ments of Performance	2			
1	the organization.		umstances unused, expired, or resplicable to sample medications.	turned medications will be mana	aged by the pharmacy or
	EP Attributes				
	New	FSA	CMS	DOC	ESP
2	pharmacy's or organi	zation's control which ir	red, or returned medications, it fol icludes procedures for preventing oplicable to sample medications.		edications to the
	New	FSA	CMS	DOC	ESP
3			side sources are used for destruct oplicable to sample medications.	ion of medications.	
	New	FSA	CMS	DOC	ESP
			Commission, © 2022 Joint Commi registered trademark of The Joint (		

Program: Ambulatory	
, , , , , , , , , , , , , , , , , , , ,	

MM.06.01.01: The organization safely administers medications.

Rationale: Not applicable.

Introduction: Not applicable

### **Elements of Performance**

Only authorized licensed independent practitioners and clinical staff administer medications. The organization defines, in writing, those who are authorized to administer medication, with or without supervision, in accordance with law and regulation.

Note: This does not prohibit self-administration of medications by patients, when indicated.

#### **EP Attributes**

New	FSA	CMS	DOC	ESP
		§416.48(a) §414.68(c)(1)(iv)	D	ESP-1

- 3 Before administration, the individual administering the medication does the following:
  - Verifies that the medication selected matches the medication order and product label
  - Visually inspects the medication for particulates, discoloration, or other loss of integrity
  - Verifies that the medication has not expired
  - Verifies that no contraindications exist
  - Verifies that the medication is being administered at the proper time, in the prescribed dose, and by the correct route
  - Discusses any unresolved concerns about the medication with the patient's licensed independent practitioner, prescriber (if different from the licensed independent practitioner), and/or staff involved with the patient's care, treatment, or services

    Note 1: For ambulatory surgical centers that elect to use The Joint Commission deemed status option: The Centers for Medicare & Medicaid Services require ambulatory surgical centers to use single dose (single-use) medication vials for only one patient.

    Note 2: For ambulatory surgical centers that elect to use The Joint Commission deemed status option: The Centers for Medicare &

Note 2: For ambulatory surgical centers that elect to use The Joint Commission deemed status option: The Centers for Medicare & Medicaid Services require ambulatory surgical centers to date multi-dose injectable medications that are used for more than one patient when they are opened, and discard them within 28 days of opening or according to the manufacturer's recommendations, whichever is more stringent. (See also MM.03.01.05, EP 2)

### **EP Attributes**

New	FSA	CMS	DOC	ESP
		§416.48(a) §414.68(c)(1)(iv)		

9 Before administering a new medication, the patient or family is informed about any potential clinically significant adverse drug reactions or other concerns regarding administration of a new medication. (See also PC.02.03.01, EP 10)

### **EP Attributes**

New	FSA	CMS	DOC	ESP
'-		§414.68(c)(1)(iv)		

Before administering a radioactive pharmaceutical for diagnostic purposes, staff verify that the dose to be administered is within 20% of the prescribed dose, or, if the dose is prescribed as a range, staff verify that the dose to be administered is within the prescribed range.

### **EP Attributes**

New FSA CMS DOC ESP
---------------------

Program: Ambulatory  pter: Medication Management  MM.06.01.05: The organization safely manages investigational medications.  Rationale: Investigational medications can be of great help to the patient. In some cases, investigational medications may represent one of a few options in the patient's plan of care. The organization contributes to the safety of patients participating in investigational or clinical medication studies by controlling and monitoring the use of these medications.  Note: For a discussion of patient rights regarding the use of investigational medications, see Standard RI.01.03.05.		
pter: Medication Management  MM.06.01.05: The organization safely manages investigational medications.  Rationale: Investigational medications can be of great help to the patient. In some cases, investigational medications may represent one of a ew options in the patient's plan of care. The organization contributes to the safety of patients participating in investigational or clinical medication studies by controlling and monitoring the use of these medications.  Note: For a discussion of patient rights regarding the use of investigational medications, see Standard RI.01.03.05.		
pter: Medication Management  MM.06.01.05: The organization safely manages investigational medications.  Rationale: Investigational medications can be of great help to the patient. In some cases, investigational medications may represent one of a ew options in the patient's plan of care. The organization contributes to the safety of patients participating in investigational or clinical medication studies by controlling and monitoring the use of these medications.  Note: For a discussion of patient rights regarding the use of investigational medications, see Standard RI.01.03.05.		
MM.06.01.05: The organization safely manages investigational medications.  Rationale: Investigational medications can be of great help to the patient. In some cases, investigational medications may represent one of a lew options in the patient's plan of care. The organization contributes to the safety of patients participating in investigational or clinical medication studies by controlling and monitoring the use of these medications.  Note: For a discussion of patient rights regarding the use of investigational medications, see Standard RI.01.03.05.		Program: Ambulatory
MM.06.01.05: The organization safely manages investigational medications.  Rationale: Investigational medications can be of great help to the patient. In some cases, investigational medications may represent one of a lew options in the patient's plan of care. The organization contributes to the safety of patients participating in investigational or clinical medication studies by controlling and monitoring the use of these medications.  Note: For a discussion of patient rights regarding the use of investigational medications, see Standard RI.01.03.05.	anter: Medication Management	
Rationale: Investigational medications can be of great help to the patient. In some cases, investigational medications may represent one of a lew options in the patient's plan of care. The organization contributes to the safety of patients participating in investigational or clinical medication studies by controlling and monitoring the use of these medications.  Note: For a discussion of patient rights regarding the use of investigational medications, see Standard RI.01.03.05.	apter reducation ranagement	
Rationale: Investigational medications can be of great help to the patient. In some cases, investigational medications may represent one of a lew options in the patient's plan of care. The organization contributes to the safety of patients participating in investigational or clinical medication studies by controlling and monitoring the use of these medications.  Note: For a discussion of patient rights regarding the use of investigational medications, see Standard RI.01.03.05.		
ew options in the patient's plan of care. The organization contributes to the safety of patients participating in investigational or clinical medication studies by controlling and monitoring the use of these medications.  Note: For a discussion of patient rights regarding the use of investigational medications, see Standard RI.01.03.05.	MM.06.01.05: The organization safely manages	investigational medications.
nedication studies by controlling and monitoring the use of these medications.  Note: For a discussion of patient rights regarding the use of investigational medications, see Standard RI.01.03.05.	Rationale: Investigational medications can be of gre	eat help to the patient. In some cases, investigational medications may represent one of a
Note: For a discussion of patient rights regarding the use of investigational medications, see Standard RI.01.03.05.		
'ntroduction. Not applicable	Note: For a discussion of patient rights regarding the	use of investigational medications, see Standard RI.01.03.05.
.iiti ouuctioii: Not applicable	Introduction: Not applicable	

### **Elements of Performance**

1 The organization follows a written process addressing the use of investigational medications that includes review, approval, supervision, and monitoring.

### **EP Attributes**

New	FSA	CMS	DOC	ESP
			D	FSP-1

2 If the organization operates a pharmacy, the process for the use of investigational medications specifies that the pharmacy controls the storage, dispensing, labeling, and distribution of investigational medications.

### **EP Attributes**

New	FSA	CMS	DOC	ESP
				ESP-1

The written process for the use of investigational medications specifies that when a patient is involved in an investigational protocol that is independent of the organization, the organization evaluates and accommodates the patient's continued participation in the protocol.

# **EP Attributes**

|--|

Program: Ambulatory	

MM.07.01.01: The organization monitors patients to determine the effects of their medication(s).

Rationale: Not applicable.

Introduction: Not applicable

### **Elements of Performance**

1 The organization monitors the patient's perception of side effects and the effectiveness of the patient's medication(s). Note: This element of performance is also applicable to sample medications.

## **EP Attributes**

New	FSA	CMS	DOC	ESP
		§414.68(c)(1)(iv)		

2 The organization monitors the patient's response to medication(s) by taking into account clinical information from the clinical record,

relevant lab values, clinical response, and medication profile.

Note 1: Monitoring the patient's response to medications is an important assessment activity for nurses, physicians, and pharmacists. In particular, monitoring the patient's response to the first dose of a new medication is essential to the safety of the patient because any adverse reactions, including serious ones, are more unpredictable if the medication has never been used before with the patient. Note 2: This element of performance is also applicable to sample medications. (See also MM.02.01.01, EP 3)

### **EP Attributes**

New	FSA	CMS	DOC	ESP
		§414.68(c)(1)(iv)		

MM.07.01.03: The organization responds to actual or potential adverse drug events, significant adverse drug reactions, and medication errors.

**Rationale:** Adverse drug reactions and medication errors place patients at considerable risk. For safe, quality care, organizations must have systems in place to respond to and monitor a patient in the event of an adverse drug reaction or medication error.

Introduction: Not applicable

### **Elements of Performance**

1 The organization follows a written process to respond to actual or potential adverse drug events, significant adverse drug reactions, and medication errors.

Note: This element of performance is also applicable to sample medications.

### **EP Attributes**

New	FSA	CMS	DOC	ESP
•		§414.68(c)(1)(iv)	D	ESP-1

2 The organization follows a written process addressing prescriber notification in the event of an adverse drug event, significant adverse drug reaction, or medication error.

Note: This element of performance is also applicable to sample medications.

#### **EP Attributes**

New	FSA	CMS	DOC	ESP
		§414.68(c)(1)(iv)	D	ESP-1

3 The organization complies with internal and external reporting requirements for actual or potential adverse drug events, significant adverse drug reactions, and medication errors.

Note: This element of performance is also applicable to sample medications.

### **EP Attributes**

New FSA CMS DOC ESP
---------------------

§414.68(c)(1)(iv)

pte	r: Medication Mana	gement			
			he effectiveness of its medica medication information. (Refe		e information)
lati	ionale: Not applicable	Э.			
ntr	oduction: Not applie	cable			
ler	ments of Performan	ce			
L	<ul> <li>Collects data on t</li> <li>Analyzes data on</li> <li>Compares data or</li> <li>system</li> </ul>	the performance of its its its medication manage ver time to identify risk	k points, levels of performance, p	atterns, trends, and variations	of its medication manageme
	Note: This element  EP Attributes	of performance is also	applicable to sample medication	s. (See also PI.01.01.01, EPs	12, 13)
	New	FSA	CMS	DOC	ESP
•	Based on analysis of opportunities for in  EP Attributes  New		cation management system.  CMS	DOC	ESP
	New  When opportunities - Takes action on ir - Evaluates its actio	FSA s are identified for improvement opportunions to confirm that the		agement system, the organizat medication management syste	ion does the following: m
	New  When opportunities - Takes action on ir - Evaluates its action Note: This element	FSA s are identified for improvement opportunions to confirm that the	CMS rovement of the medication manaties identified as priorities for its by resulted in improvements	agement system, the organizat medication management syste	tion does the following: m
	opportunities for in  EP Attributes  New  When opportunities - Takes action on ir - Evaluates its action Note: This element  EP Attributes	FSA  s are identified for implemprovement opportunitions to confirm that the coff performance is also	CMS  rovement of the medication mana ties identified as priorities for its by resulted in improvements by applicable to sample medication	agement system, the organizat medication management syste s. (See also PI.04.01.01, EP 2	tion does the following: m )
5	When opportunities - Takes action on ir - Evaluates its action Note: This element  EP Attributes  New	FSA  s are identified for important opportunitions to confirm that the of performance is also	CMS  rovement of the medication mana ties identified as priorities for its by resulted in improvements by applicable to sample medication	agement system, the organizat medication management syste s. (See also PI.04.01.01, EP 2 DOC	cion does the following: m ) ESP
,	when opportunities - Takes action on ir - Evaluates its action to: This element - New - Ne	FSA  s are identified for important opportunitions to confirm that the of performance is also	CMS  rovement of the medication manaties identified as priorities for its by resulted in improvements applicable to sample medication CMS	agement system, the organizat medication management syste s. (See also PI.04.01.01, EP 2 DOC	cion does the following: m ) ESP
5	New  When opportunities - Takes action on ir - Evaluates its action Note: This element  EP Attributes  New  The organization ta or not sustained.	FSA  s are identified for important opportunitions to confirm that the of performance is also	CMS  rovement of the medication manaties identified as priorities for its by resulted in improvements applicable to sample medication CMS	agement system, the organizat medication management syste s. (See also PI.04.01.01, EP 2 DOC	cion does the following: m ) ESP
,	When opportunities Takes action on ir Evaluates its action Note: This element EP Attributes  New  The organization ta or not sustained.  EP Attributes  New  When automatic dis	FSA  FSA  FSA  FSA  FSA  FSA  FSA  FSA	CMS  rovement of the medication manaties identified as priorities for its by resulted in improvements of applicable to sample medication CMS	agement system, the organizate medication management systems. (See also PI.04.01.01, EP 2  DOC  DOC  DOC  DOC	ESP  ESP  ESP  ESP
,	When opportunities Takes action on ir Evaluates its action on ir Evaluates its action on ir When opportunities New The organization to or not sustained.  EP Attributes  New  When automatic distinct will be reviewed.	FSA  FSA  FSA  FSA  FSA  FSA  FSA  FSA	CMS  rovement of the medication manaties identified as priorities for its by resulted in improvements applicable to sample medication  CMS  CMS  CMS  CMS  CMS	agement system, the organizate medication management systems. (See also PI.04.01.01, EP 2  DOC  DOC  DOC  DOC	ESP  ESP  ESP  ESP